{"id":1295,"date":"2022-09-09T16:44:55","date_gmt":"2022-09-09T14:44:55","guid":{"rendered":"https:\/\/lensounds.com\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/"},"modified":"2026-03-07T07:38:24","modified_gmt":"2026-03-07T06:38:24","slug":"pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer","status":"publish","type":"science","link":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/","title":{"rendered":"PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer"},"content":{"rendered":"\n<p style=\"font-style:italic;font-weight:400\">Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Informations cl\u00e9s<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ClinicalTrials.gov ID<\/strong> : NCT04897763<\/li>\n<li><strong>Sponsor<\/strong> : Institut Cancerologie de l&#8217;Ouest<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Official Title<\/h2>\n\n\n\n<p>A Pilot Open-label, Feasibility Study to Assess safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Brief Summary<\/h2>\n\n\n\n<p>There is a real need for treatment of NMIBC. Currently, treatment options include Bacillus Calmette-Guerin (BCG) intravesical immunotherapy and mitomycin C chemotherapy. These therapies are efficient for some time but relapses repeat them at more and more close intervals and finally patients are refractory to them and require a radical cystectomy.<\/p>\n\n\n\n<p>CAIX is expressed in 70% to 90% of bladder cancers but not in normal urothelial tissue. CAIX is expressed on the membrane of Non-Muscle-Invasive Bladder Cancer cells.<\/p>\n\n\n\n<p>Girentuximab, an anti-CAIX antibody could be a promising target in NMIBC. PET\/CT with Girentuximab labelled with 89Zirconium will be used for diagnosis purpose. 89Zr-Girentuximab will be administered by intravesical instillation.<\/p>\n\n\n\n<p>In this study, patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) will be enrolled in this study after confirmation of their eligibility.\n\nA single intravesical administration of 89Zr-Girentuximab will be performed at day 0.\n\nMultiple PET\/CT imaging sessions will be performed on day 0, day 1 and day 2 in order to evaluate the bladder and the whole body 89Zr girentuximab uptake.<\/p>\n\n\n\n<p style=\"font-size:clamp(0.875rem, 0.875rem + ((1vw - 0.2rem) * 0.037), 0.9rem);\"><strong>Source<\/strong> : <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04897763\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov \u2013 NCT04897763<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ClinicalTrials.gov ID NCT04897763 \u2013 Sponsor Institut Cancerologie de l&#8217;Ouest \u2013 ClinicalTrials.gov \u2013 NCT04897763<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"science_category":[50],"class_list":["post-1295","science","type-science","status-publish","hentry","science_category-ato-101-publications"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer - Atonco<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer - Atonco\" \/>\n<meta property=\"og:description\" content=\"ClinicalTrials.gov ID NCT04897763 \u2013 Sponsor Institut Cancerologie de l&#039;Ouest \u2013 ClinicalTrials.gov \u2013 NCT04897763\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-07T06:38:24+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\\\/\",\"name\":\"PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer - Atonco\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"datePublished\":\"2022-09-09T14:44:55+00:00\",\"dateModified\":\"2026-03-07T06:38:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Science\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/science\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer - Atonco","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/","og_locale":"en_US","og_type":"article","og_title":"PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer - Atonco","og_description":"ClinicalTrials.gov ID NCT04897763 \u2013 Sponsor Institut Cancerologie de l'Ouest \u2013 ClinicalTrials.gov \u2013 NCT04897763","og_url":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/","og_site_name":"Atonco","article_modified_time":"2026-03-07T06:38:24+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/","url":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/","name":"PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer - Atonco","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"datePublished":"2022-09-09T14:44:55+00:00","dateModified":"2026-03-07T06:38:24+00:00","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/science\/pertinence-89zr-girentuximab-imaging-in-non-muscle-invasive-bladder-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Science","item":"https:\/\/atonco-pharma.com\/en\/science\/"},{"@type":"ListItem","position":3,"name":"PERTINENCE \u2013 89Zr-Girentuximab Imaging in Non-Muscle-Invasive Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science\/1295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/science"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1295"}],"wp:term":[{"taxonomy":"science_category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/science_category?post=1295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}